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Available online 2 April 2016Backgound: The favorable effects of insulin during myocardial infarction (MI) remain unclear due to the
divergence between mechanistic studies and clinical trials of exogenous insulin administration. The rs7903146
polymorphism of the transcription factor 7-like 2 (TCF7L2) gene is associated with attenuated insulin secretion.
Methods: In non-diabetic patients with ST-elevation MI (STEMI), using such a model of genetically determined
down-regulation of endogenous insulin secretion we investigated the change in plasma insulin, C-peptide,
interleukin-2 (IL-2), C-reactive protein (CRP), and nitric oxide (NOx) levels between admission (D1) and the
ﬁfth day after MI (D5). Coronary angiography and ﬂow-mediated dilation (FMD) were performed at admission
and 30 days after MI, respectively. Homeostasis Model Assessment estimated insulin secretion (HOMA2%β)
and insulin sensitivity (HOMA2%S).
Results: Although glycemia did not differ between genotypes, carriers of the T-allele had lower HOMA2%β and
higher HOMA2%S at both D1 and D5. As compared with non-carriers, T-allele carriers had higher plasma IL-2
and CRP at D5, higher intracoronary thrombus grade, lower FMDandNOx change betweenD1 andD5 and higher
30-day mortality.
Conclusion: In non-diabetic STEMI patients, the rs7903146 TCF7L2 gene polymorphism is associatedwith lower in-
sulin secretion, worse endothelial function, higher coronary thrombotic burden, and higher short-termmortality.
General signiﬁcance: During the acute phase of MI, a lower capacity of insulin secretion may inﬂuence clinical
outcome.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Abundant data ranging from cell models to mechanistic studies in
human subjects have indicated that insulin may offer a wide array of
potentially positive effects on the cardiovascular system. For example,
insulin has been shown to improve endothelial function [1], reduceata analyses and prepared the
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. This is an open access article underinﬂammatory response [2], increase myocardial blood ﬂow [3], and at-
tenuate both platelet aggregation [4] and pro-thrombotic factors [5].
These effects are particularly interesting in the setting of myocardial in-
farction (MI), which iswhen thesemechanisms are playing pivotal roles
in determining clinical outcome. Thus, it is conceivable that β-cell
capacity may be intrinsically involved in the adaptive response to MI.
Recently, a variant of the transcription factor 7-like 2 (TCF7L2) gene,
the rs7903146 (IVS3CNT), was associated with development of type 2
diabetes (T2D) [6,7]. It is a rather common single nucleotide polymor-
phism (SNP) that is associated with posttranscriptional impairment in
insulin secretion [8]but has no effect on insulin sensitivity [9,10]. In
this context, we hypothesize that carriers and non-carriers of the
rs7903146 mutant allele portray different endogenous insulin output
during the acute phase of MI and, if so, they will demonstrate distinct
adaptive responses to MI. Hence, we investigated in nondiabetic
individuals with MI the association between rs7903146 genotypethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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association with the recurrence of cardiovascular events.2. Research design and methods
2.1. Study patients
Patients are participants in the Brasilia Heart Study (ClinicalTrials.gov
Identiﬁer: NCT02062554), an ongoing prospective cohort of consecu-
tive ST-elevation MI (STEMI) patients that were enrolled between
May 2006 and October 2011 (ﬂow diagram in Fig. 1). Inclusion criteria
are as follows: (i) b24 h after the onset of MI symptoms, (ii) ST-
segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal
plane) in two contiguous leads, and (iii) myocardial necrosis, as
evidenced by an increase to at least one value above the 99th percentile
above the reference limit of CK-MB (25 U/L) and troponin I
(0.04 ng/mL) followed by a decline of both. Individuals with a previous
diagnosis of diabetes, use of hypoglycemiants, or glycosylated hemoglo-
bin (HbA1c) ≥6.5% (48 mmol/mol) were excluded from the study.
There was no interference with patient treatment, which was decided
by the assistant physician following a hospital protocol based on the
current ACC/AHA guidelines for STEMI. The physicians involved in the
treatment of the patients were blind to all analyses performed in the
study. The local Ethics Committee approved the study and all partici-
pants signed an informed consent. The authors vouch for the integrity
of the data and all analyses. All authors have read and agree to theman-
uscript as written.Fig. 1. Flow-chart of pa2.2. Biochemical analysis
Blood samples were obtained at D1, i.e. b24-h fromMI onset, and at
day ﬁve following MI (D5). Samples were centrifuged for 10 min at
3500 rpm. Plasma was aliquoted for storage at−80 °C. The following
methods were used for analyses of plasma samples: glucose (GOD-
PAP, Roche Diagnostics, Mannheim, Germany), total cholesterol
(CHOD-PAP, Roche Diagnostics, Mannheim, Germany), triglycerides
(TG) (GPO-PAP, Roche Diagnostics, Mannheim, Germany), high-
density lipoprotein cholesterol (HDL-C) (RocheDiagnostics,Mannheim,
Germany), C-reactive protein (CRP) (Cardiophase, Dade Behring, Mar-
burg, Germany), 8-isoprostane (EIA kit, Cayman Chemical Company,
Ann Arbor, MI, USA), interleukin-2 (IL-2) (Fluorokine® MAP Human
IL-2 Kit, R&D Systems, Minneapolis, MN, USA), and HbA1c (Variant II,
Bio-Rad Laboratories, Hercules, CA, USA). Plasma levels of nitrite and ni-
trate (NOx) were measured by an NO chemiluminescence analyzer
(model NOA, Sievers Instruments, Boulder, CO) after reduction with
acidic vanadium (III) chloride. Plasma insulin and C-peptide concentra-
tions were determined by electrochemiluminescence (Roche Diagnos-
tics, Mannheim, USA) and by imunoquimioluminescence (Immulite
2000, Diagnostic Products Corporation, Los Angeles, CA, USA), respec-
tively. The Homeostasis Model Assessment version 2 (HOMA2) was
used to estimate β-cell function (HOMA2%β) and insulin sensitivity
(HOMA2%S), which were both calculated with HOMA2 calculator ver-
sion 2.2. [11] We used fasting plasma insulin levels to compute
HOMA2%S and plasma C-peptide to compute HOMA2%β. The accuracy
of HOMA2 index during STEMI was previously validated in STEMI
patients by euglycemic hyperinsulinemic clamp in our laboratory. [12]tient enrollment.
161R. Cintra et al. / BBA Clinical 5 (2016) 159–1652.3. Genotyping
DNA was extracted from buffy coat using QIAamp DNA Blood Mini
Kit (Quiagen, GmBHHilden) and stored at−20 °C. Genotypingwas de-
termined by real-time ampliﬁcation refractory mutation system using
allele-speciﬁc primers. Two forward primers were designedwith amis-
match in their last 3′ nucleotide in such a way that each was speciﬁc for
the two variants of the polymorphism (NCBI RefSNP: 7903146): variant
C GAACAATTAGAGAGCTAAGCACTTTTTAGAAAC; and variant T GAACAA
TTAGAGAGCTAAGCACTTTTTAGAGAT. A common reverse primer with-
out mismatches, AGATGAAATGTAGCAGTGAAGTGC, was designed
downstreamof the polymorphic site. Two parallel real-time polymerase
chain reactionswere conductedwith the combined use of allele-speciﬁc
forward primers and a common reverse primer, in duplicates. The am-
pliﬁcation program was: DNA polymerase activation at 95 °C for
10 min, followed by 35 repeated cycles of denaturation at 95 °C for
15 s and annealing-extension at 60 °C for 1 min. Ampliﬁcation speciﬁc-
ity was tested by melt curve analysis, which was performed by heating
the samples from 60 °C to 95 °C at increments of 0.3 °C while recording
the ﬂuorescence signal decay. Genotyping reactions were performed in
batches of 20 samples. Gene ampliﬁcation was carried out using a
SYBR® green assay (Maxima SYBR® Green qPCR Master Mix 2X,
Fermentas, Glen Burnie, MD, USA) in a Step One™ Real-Time qPCR Sys-
tem (Applied Biosystems, Foster City, CA, USA).2.4. Coronary angiography
Coronary angiography was systematically performed on all patients
enrolled to assess coronary thrombotic burden, degree of reperfusion,
and severity of atherosclerotic disease. Thrombotic burdenwas estimat-
ed at the culprit coronary artery according to the Thrombolysis In
Myocardial Infarction (TIMI) Thrombus Grade Scale as follows:
(i) Grade 0—no angiographic evidence of thrombus is present; (ii)
Grade 1—possible thrombus, with reduced contrast density, haziness,
irregular lesion contour, or a smooth convex at the site of total occlusion
suggestive but not diagnostic of thrombus; (iii) Grade 2—deﬁnite
thrombus, with greatest dimensions less than half of vessel diameter;
(iv) Grade 3—deﬁnite thrombus but with greatest dimensions less
than half but greater than two vessel diameters; (v) Grade 4—deﬁnite
thrombus greater than two vessel diameters; and (vi) Grade 5—total oc-
clusion [13]. The Gensini score estimated coronary disease severity.
Coronary ﬂow in the culprit artery was measured using TIMI ﬂow
grade and Myocardial Blush Grade (MBG), and was assessed after
angioplasty in patients who underwent primary percutaneous coronary
intervention (PCI) or at the earliest possible angiogram performed after
thrombolysis.2.5. Brachial artery reactivity
Brachial artery measurements were performed using a high-
resolution ultrasound (IE33 and 3–9 MHz linear transducer; Philips
Medical Systems, Bothell, Washington, USA) after over-night fasting
30 days after admission (D30) and vasoactive medications were with-
drawn 24 h before assessment. After 10 min of rest in a quiet room
with the temperature controlled around 22 °C, the brachial artery was
located above the elbow, and a longitudinal image of 6 to 8 cm was
taken as the resting scan. A blood pressure cuff was placed on the
forearm and inﬂated to 50 mm Hg above the systolic blood pressure
for 5 min. The cuff was deﬂated, and the ﬂow-mediated dilation
(FMD) scan was obtained for 2 min. The percentage change in diameter
for FMD was calculated in relation to the respective baseline scans. The
same experienced physician, who was blinded to patients' data,
analyzed brachial artery reactivity. The intra-observer reproducibility
was 95%.2.6. Cardiac magnetic resonance imaging (CMRI)
CMRI studies were carried out using a MRI scanner with a 1.5-T
(Signa CV/i, GEMedical Systems,Waukesha,WI) equippedwith a gradi-
ent of high performance (gradient strength 40 mT/m; maximum slew
rate 150 mT/m/s) and a four element phased array cardiac coil. Areas
of MI were quantiﬁed on the gadolinium-based delayed enhancement
myocardial images at D30 to quantify MI mass, left ventricle (LV) vol-
umes, and ejection fraction. Areas of microvascular obstruction (MVO)
were deﬁned as subendocardial hypo-enhanced regions surrounded
by hyperenhancement and were included as part of the core infarct.
On cine-CMRI, left ventricle (LV) volumes and ejection fraction were
measured by ReportCard software (GE Medical Systems, Waukesha,
WI) by applying Simpson's method.
2.7. Statistical analysis
Normally distributed data is presented as mean ± standard
deviation and skewed data is presented in the form of median
(interquartile range). Log transformation was applied to skewed
variables in order to use parametric tests. The change in values for the
variables was calculated as the relative difference between D5 and D1.
Analysis of covariance (ANCOVA) was used for FMD, NOx, glycaemia,
HDL-C, LDL-C, TG, CRP, 8-isoprostane, IL-2, insulinemia, C peptide,
HOMA2%S and HOMA2%β. ANCOVA was used to compare these vari-
ables between groups after analysis with histograms, normality plots
and residual scatter plots that tested for linearity, normality and vari-
ance. Mortality in the ﬁrst 30 days was investigated by chi-square and
binary logistic regression. A b0.05 two-sided p-value was considered
signiﬁcant. SPSS software version 21.0 was used for all analyses.
3. Results
3.1. Baseline characteristics
A total of 118 patients were homozygous for wild-type C-allele, 23
were homozygous for the mutant T-allele and 129 were heterozygous.
The Hardy–Weinberg equilibrium was evaluated using the χ2 test
(p = 0.0158), in which the T-allele was considered dominant and the
frequency of the recessive allele was 0.33. Carriers of the T-allele were
grouped together in order to increase statistical power. As shown in
Table 1, study participants did not differ in terms of demographic
characteristics, except that a larger percentage of patients with the T-
allele used beta-blocker during hospitalization. Small differences were
found in plasma TG and HDL-C between carriers and non-carriers of
the T-allele.
3.2. Glucose metabolism
As shown in Table 3, plasma insulin levels were lower in the T-allele
carriers at both D1 and D5 as compared to patients with CC genotype.
Plasma C-peptide level was similar at D1 across genotype groups but
lower at D5 in T-allele carriers. Consequently, the latter group had a
more intense decline of C-peptide levels between D1 and D5.
Consistently, pancreatic β-cell function estimated by HOMA2%β was
lower in the T-allele carriers at D1 and D5.
Insulin sensitivity measured by HOMA2%S was higher in T-allele
carriers at D1 and D5 as well as the change of HOMA2%S between D1
and D5. Blood glucose was similar across the genotype groups at D1
and D5 indicating that the lower insulin output was balanced by the
higher insulin sensitivity.
3.3. Oxidative stress and inﬂammatory response
As shown in Table 3, systemic inﬂammatory activity at D5 estimated
by plasma CRP levels was higher in carriers of the T-allele than in their
Table 1
Characteristics of studied patients grouped by the presence of the T-allele.
TCF7L2 rs7903146 p
CC CT + TT
n 118 152 (129 CT + 23 TT)
Male (%) 75 79 0.39
Age (years) 61.9 ± 10.5 62.3 ± 12.7 0.77
BMI (kg/m2) 25.5(4.8) 25.5(5.1) 0.87
Waist circumference (cm) 94.7 ± 8.9 95.2 ± 12.2 0.74
Family history for CAD (%) 42 41 0.88
Hypertension (%) 56 54 0.75
Smoking habit (%) 37 45 0.18
HDL-C (mg/dL) 39(17) 38(13) b0.001
LDL-C (mg/dL) 130 ± 39 118 ± 42 0.28
TG (mg/dL) 104(77) 121(87) b0.001
CK-MB Peak (UI/ml) 168(231) 155(202) 0.54
Creatinine clearance 72 ± 20 70 ± 22 0.52
Sedentarity (%) 50 57 0.23
Prior MI (%) 10 7 0.30
Dyslipidemia (%) 30 30 0.95
Reperfusion therapy (%) 76 72 0.66
Time to reperfusion therapy (%)
≤2 h 53 61 0.12
≤6 h 84 88 0.23
ASA use (%) 94 96 0.48
Beta-blocker use (%) 60 75 0.01
UFH or LMWH (%) 93 93 0.65
Clopidogrel use (%) 96 98 0.50
ACEi or ARB (%) 60 49 0.1
Statin use (%) 70 66 0.47
Hb1Ac (%) 5.8(0.6) 5.8(0.53) 0.80
BMI: body mass index; CK-MB: creatine kinase MB; MI: myocardial infarction; ASA:
acetylsalicylic acid; UFH: unfractionated heparin; LMWH: Low-molecularweight heparin;
HbA1c: glycosylated hemoglobin; ACEi: angiotension converting enzyme inhibitor; ARB:
angiotensin receptor blocker; Creatinine Clearance calculated by Cockcroft-Gault; D1:
Day 1 of myocardial infarction.
Table 2
Angiographic and CMRI characteristics of study subjects.
TCF7L2 rs7903146 p
CC CT + TT
Angiographic characteristics
Three-vessel disease (%) 16 20 0.32
Two-vessel disease (%) 34 31 0.40
One-vessel disease (%) 33 36 0.61
Left main coronary disease (%) 6 5 0.58
Gensini score 40(58) 48(62) 0.36
Syntax 8(13) 8(14) 0.74
Post-reperfusion TIMI-ﬂow b3 (%) 17 10 0.61
Post-reperfusion MBG b3 (%) 32 42 0.20
Intracoronary thrombus (%) 22 36 0.03
TIMI Thrombus Grade ≥3 (%) 15 28 0.02
Pre-PCI TIMI ﬂow 0 (%) 10 20 0.02
Pre-PCI TIMI ﬂow 0/1 (%) 13 22 0.01
CMRI
Infarct size (g) 12(13) 12(12) 0.41
Infarct size (%) 10(9) 10.5(8) 0.34
Left ventricle diastolic diameter (mm) 52 ± 8 49 ± 6 0.19
Left ventricle ejection fraction (%) 46 ± 15 46 ± 11 0.90
CMRI: cardiac magnetic resonance imaging.
Table 3
Plasma levels of lipids, glucose homeostasis, and inﬂammatory markers.
TCF7L2 rs7903146 p⁎
CC CT + TT
Glucose homeostasis
Insulin D1 (μIU/mL) 21(29) 18(23) 0.006
Insulin D5 (μIU/mL) 12(16) 10(10) b0.001
Delta Insulin −8(28) −5(20) b0.001
C-Peptide D1(ng/dL) 5.1 ± 3.1 4.9 ± 3.1 0.97
C-Peptide D5 (ng/dL) 4.5 ± 3.0 4.0 ± 2.2 b0.001
Delta C-Peptide −0.8(3.4) −0.6(3.2) b0.001
Glycaemia D1 (mg/dL) 115(31) 116(33) 0.59
Glycaemia D5 (mg/dL) 101(24) 101(20) 0.54
Delta Glycaemia −11(32) −13(30) 0.53
HOMA2%S D1 (%) 35(55) 42(65) 0.020
HOMA2%S D5 (%) 62(83) 73(76) b0.001
HOMA2%S Delta 17(80) 23(65) b0.001
HOMA2%β D1 (%) 112(83) 100(94) 0.003
HOMA2%β D5 (%) 105(82) 98(77) 0.002
HOMA2%β Delta −9.4(96) −7.9(64) b0.001
Inﬂammatory markers
CRP D1 (mg/L) 0.4(0.8) 0.6(1.2) 0.99
CRP D5 (mg/L) 2.9(5.9) 3.4(5.1) b0.001
Delta CRP 2.2(5.7) 2.3(5.2) b0.001
IL-2 D1 (pg/mL) 0.6(2.4) 0.6(1.5) 0.69
IL-2 D5 (pg/mL) 5.0 ± 3 6.4 ± 4 0.04
Delta IL-2 3.4 ± 2 5.0 ± 4 0.02
8-isoprostane D1 (pg/mL) 34.7 ± 17 40.1 ± 22 0.32
8-isoprostane D5 (pg/mL) 28.4 ± 13 26.1 ± 10 0.71
Delta 8-isoprostane −6.3 ± 19 −10.6 ± 23 0.36
⁎ p value calculated by ANCOVA adjusted for sex, age, waist circumference, and baseline
levels where ﬁtting.
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the increase in IL-2 from D1 to D5 were higher when compared to
their counterpart. No difference was observed in 8-isoprostane levels
between groups.
3.4. Endothelial function and plasma pool of NOx
In comparison with the CC genotype group, CT + TT subjects had a
lower increment in plasma levels of NOx from D1 to D5 [6.5 (14) vs.
4.9(14) μmol/L, respectively; p b 0.001]. In addition, carriers of the T-
allele (6.99 ± 4.7%) presented a signiﬁcantly lower FMD at D30 than
homozygotes for the C-allele (7.74 ± 4.6%; p = 0.001). This difference
remained signiﬁcant even after adjustment for gender, age, and waist
circumference (p = 0.001).
3.5. Coronary angiography and CMRI
As shown in Table 2, carriers of the T-allele weremore likely to have
intracoronary thrombus and almost twice as likely to present a TIMI
thrombus grade ≥3 or a pre-angioplasty TIMI ﬂow grade of 0 or 1. Ge-
notype groups shared similar characteristics regarding coronary artery
disease severity, post-reperfusion TIMI ﬂow and myocardial blush
grade. Likewise, CMRI studies showed that groups did not differ in MI
size, LV diastolic diameter or ejection fraction.
3.6. All-cause mortality
In the ﬁrst 30 days after the index event, 22 primary endpoints were
adjudicated (as shown Table 4). In this period of time, as depicted in
Fig. 2, total mortality was signiﬁcantly higher in the group of patients
with the CT+TT genotypes when compared to their counterpart
(11.2% vs. 4.2%; p = 0.03). The hazard ratio (HR) for this association
was 2.85 (95% CI 1.03–6.99; p = 0.038) in an unadjusted analysis and2.86 (95% CI of 1.02 to 8.00; p = 0.046) after adjusting for age and
sex. The statistical signiﬁcance of the association between the genotype
and mortality was lost after adjustment for HOMA2%β in the Cox re-
gression model (p = 0.16). Although beta-blocker was administered
less frequently for patients with the CC genotype, there were no
differences in functional class or hemodynamic status between groups.
Also, there no signiﬁcant association between mortality at 30 days and
beta-blocker use.
4. Discussion
To the best of our knowledge, this is the ﬁrst study to report the
association between the TCF7L2 rs7903146 polymorphism and lower
insulin secretion during STEMI. This mutation also inﬂuenced the
Table 4
Causes of death in the ﬁrst 30 days after admission.
Case number TCF7L2 Genotype Day after MI Cause
1 CT 1st Day VT/VF
2 CT 3rd Day Cardiogenic shock
3 CT 2nd Day VT/VF
4 CT 4th Day VT/VF
5 CT 5th Day VT/VF
6 CT 9th Day Sudden Death
7 CT 4th Day VT/VF
8 CT 3rd Day VT/VF
9 CT 5th Day VT/VF
10 CC 2nd Day VT/VF
11 CT 5th Day Fatal recurrent MI
12 TT 19th Day Sudden Death
13 CT 2nd Day Fatal recurrent MI
14 CT 2nd Day VT/VF
15 CC 1st Day VT/VF
16 CC 23rd Day Fatal recurrent MI
17 CT 1st Day VT/VF
18 CC 24th Day Fatal recurrent MI
19 CC 25th Day Cardiogenic shock
20 TT 2nd Day Fatal recurrent MI
21 CT 5th Day Stroke
22 CT 3rd Day VT/VF
VT: ventricular tachycardia; VF: ventricular ﬁbrillation; MI: myocardial infarction.
163R. Cintra et al. / BBA Clinical 5 (2016) 159–165inﬂammatory, thrombotic, and endothelial response to STEMI. In
addition, despite the preliminary nature of the survival data, the associ-
ation between genotype and 30-day mortality was dependent on
HOMA2%B, suggesting that insulin secretion has an important role in
this interaction.
Comprising the effector portion of the Wnt signaling pathway,
TCF7L2 has been linked to regulating β-cell survival and insulin
secretion. The SNP rs7903146 of the TCF7L2 gene has been linked to
post-transcriptional impairment in insulin production [14]. Consistent-
ly, the presence of the mutant T-allele of TCF7L2 rs7903146 was
associated with insulin secretion in diabetic and non-diabetic individ-
uals in a wide range of age, ethnicity and physical activity [15,16]. The
presence of the T-allele is also associated to the longterm incidence of
diabetes in obese [17] and non-obese subjects with high cardiovascular
risk [18].The current study added to this body of evidence the concept
that carriers of the mutant T-allele also have an impaired insulin
secretion under conditions of metabolic stress.
In contrast to previous reports [10,19], we found that carriers of the
T-allele had higher insulin sensitivity than the other study participants.
Thisﬁndingwas probably due to the exclusion of T-allele carrierswhose
insulin sensitivity was not high enough to prevent the manifestation of
diabetes, which was an exclusion criterion of the study.Fig. 2. Kaplan–Meier actuarial analysis of 30 days survival based on rs7903146 T allele
presence in non-diabetic MI patients.As remarked above, recent studies have demonstrated that, through
the same signaling pathways involved in glucose lowering, insulin
wields anti-inﬂammatory effects [2]. Indeed, insulin infusion reduces
activation of nuclear factor κB (NFκB) and secretion of soluble intercel-
lular adhesion molecule-1 (sICAM-1) and monocyte chemoattractant
protein-1 (MCP-1) [20]. DuringMI, insulin infusion targeted tomaintain
blood glucose less than 140 mg/dL reduced plasma CRP and serum
amyloid A [21]. Although we were not able to identify differences in
oxidative stress as estimated by 8-isoprostane levels between
genotypes, we found that patients with CC genotype have reduced
values of IL-2 and CRP. Since both CRP and IL-2 are robust markers of
inﬂammatory response during STEMI one could infer that under
stressful conditions, such as MI, this polymorphism and its effect on
insulin output could potentially inﬂuence the inﬂammatory response.
According to in vitro studies using endothelial cells, insulin increases
NO production by activating endothelial NO synthase (eNOS) via the
phosphatidylinositol 3-kinase pathway [22]. This effect has beenmainly
considered as the mechanism by which physiologic concentrations of
insulin induce arterial vasodilation [23] and increase myocardial blood
ﬂow in a dose-dependent manner [3]. Accordingly, we observed that
patientswith the CC genotype,whohad higherHOMA2%B, also present-
ed higher FMD and NOx levels.
Upon assessment of coronary angiography results, we found that
carriers of the mutated-allele also had a higher thrombotic burden. So
far, this is the ﬁrst report of the interaction between insulin and
thrombus generation during acute coronary syndromes. The insulin
receptor has been previously described in human platelets [24].
Furthermore, insulin has been reported to have an anti-aggregating
effect in vitro and in vivo [4,25,26]. From a mechanistic point of view,
higher physiologic concentrations of insulin stimulate NO production
and increases platelet content of cGMP and cAMP [4]. In parallel, insulin
may also reduce plasma concentration of tissue factor (TF) and plasmin-
ogen activator inhibitor-1 (PAI-1), thus bothmitigating thrombogenesis
and favoring thrombolysis [5].
From a clinical perspective, our study suggests that the presence of
the T-allele may favor an enhanced mortality during the ﬁrst 30 days
after STEMI. This association looses statistical signiﬁcance when adjust-
ed by HOMA2%B, suggesting a mediating role for insulin secretion.
These are preliminary ﬁndings that are nonetheless consistent with
the above-mentioned effects on the inﬂammatory response, endothelial
function, and thrombogenesis. Granted there is an apparent contradic-
tion between our ﬁndings and clinical trials testing exogenous insulin
administration in patients with MI [27,28]. However, marked
differences exist between endogenous and exogenous insulin supply.
For instance, exogenous insulin administration is non-pulsatile and
reaches a considerably higher concentration (up to 40 times higher)
[29]. In fact, exogenous non-pulsatile infusions or supraphysiological
insulin doses favor insulin resistance [30], gluconeogenesis [31],
endothelial dysfunction [32], and higher systemic inﬂammatory activity
[33].
Timing till insulin infusion after myocardial ischemia could also
justify the difference between this study and exogenous insulin infusion
trials duringMI. Although late insulin infusion did not reduce cardiovas-
cular events in STEMI patients, this beneﬁt was seen when insulin
infusion was started early after STEMI [34]. In our study, it is reasonable
to suggest that the time between stimuli and insulin response was
minimal and distinct between carriers and non-carriers of the T-allele
because there is no insulin administration
Some limitations of our study should be acknowledged. Firstly, we
did not account for possible additive effects of other known TCF7L2
polymorphisms or other T2D risk alleles unrelated to theWnt pathway.
For example, a possible crosstalk between theWnt and forkhead box O
(FOXO) pathways could attenuate inﬂammatory response [14] and
favor eNOS activity [35]. Moreover, the TCF7L2 gene is also expressed
in non-pancreatic cells [36] and may exert distinct effects that impact
recurrence of events in a manner that is unrelated to insulin secretion
164 R. Cintra et al. / BBA Clinical 5 (2016) 159–165per se. Thus, it is possible that a reduced insulin secretion is not the only
mechanism that would beneﬁt STEMI patients. Nonetheless, the effect
on insulin secretion cannot be neglected because the presence of the
T-allele hadmarked impact in insulin secretory function and the adjust-
ment for insulin secretion nulliﬁed the association between the poly-
morphism and mortality after MI.
We found imbalance favoring a slightly higher frequency of T-allele
carriers (56%) as compared with subjects without coronary artery
disease (51%) [17], and to those with chronic stable disease (53%)
[37]. This is in line with the higher severity of coronary artery disease
in non-diabetic T-allele carriers [37] and higher incidence of stroke in
individuals with TT-genotype [18]. We also found a lower frequency
of TT-genotype (8.5%) in our cohort, which may represent a survival
bias since patients who died before hospitalization were not assessed.
These assumptions, however, requires further investigation.
In conclusion, the TCF7L2 rs7903146 is associated with decreased
insulin secretion, increased inﬂammatory response, thrombotic burden,
and endothelial dysfunction in STEMI patients. By comparing distinct
insulin secretory phenotypes, this ﬁnding supports the concept that
carriers of TCF7L2 rs7903146 C allele have a favorable impact on the
adaptive response and clinical outcome of STEMI patients.
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